Feb. 3 at 2:36 PM
$OMER this is the weirdest spot I've ever seen a company. Game changing catalysts with NVO partnership, removed the dilution overhead, and FDA approval and becoming a standard of care in the US and soon Europe for TA-TMA.
Treatment cost surpassed most analyst estimates at 36k a vial.
Estimating a conservative
$500M a year after ramp up with it doubling after Europe approves Yarsoploma ( FDA drugs nearly always make their way to Europe)
And it's still wedged and shorted for some delusional, angry base of wallstreet regretful decisions.
Just spark the rally to
$75-
$100 and let the shorts wake up to the pain.
